AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie lumigan/Ganfort (bimatoprost) — U.S. net revenues ($M) ($M)
Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Key Product Revenues
Latest, FY2025
189
Period ended Dec 31, 2025
Change on a year earlier
+1.1%
187 in FY2024
History
8 years
Since FY2018
Sources
6
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Lumigan/Ganfort (bimatoprost) — U.S. net revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 189 | +1.1% | Form 10-K (filed 2026-02-20) ↗ |
| FY2024 | Dec 31, 2024 | 187 | +8.1% | Form 10-K (filed 2026-02-20) ↗ |
| FY2023 | Dec 31, 2023 | 173 | -28.5% | Form 10-K (filed 2026-02-20) ↗ |
| FY2022 | Dec 31, 2022 | 242 | -11.4% | Form 10-K (filed 2025-02-14) ↗ |
| FY2021 | Dec 31, 2021 | 273 | +65.5% | Form 10-K (filed 2024-02-20) ↗ |
| FY2020 | Dec 31, 2020 | 165 | – | Form 10-K (filed 2023-02-17) ↗ |
| FY2019 | Dec 31, 2019 | 0 | – | Form 10-K (filed 2022-02-18) ↗ |
| FY2018 | Dec 31, 2018 | 0 | – | Form 10-K (filed 2021-02-19) ↗ |
Breakdown
What makes up lumigan/ganfort (bimatoprost) — u.s. net revenues ($m)
Cite this data
StockData. (2026). AbbVie Lumigan/Ganfort (bimatoprost) — U.S. net revenues ($M) ($M), annual FY2018–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/lumigan_us
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.